Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comtess vs Cabaseril as add-on to levodopa in Parkinson's disease with wearing-off
2004-002643-27Phase 4Completed
- Sponsor
- Orion Corporation
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of entacapone and cabergoline in Parkinson's disease (PD) (2 arms), sponsored by Orion Corporation. Primary endpoint: Change in OFF-time at 12 weeks. Started Oct 2004; status: completed.
02
Drugs
entacaponecabergoline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2004-002643-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002643-27.